IN8bio Inc.

0.18
-0.00 (-1.37%)
At close: Apr 24, 2025, 3:58 PM
-1.37%
Bid 0.17
Market Cap 14.85M
Revenue (ttm) n/a
Net Income (ttm) -30.44M
EPS (ttm) -0.6
PE Ratio (ttm) -0.3
Forward PE -0.84
Analyst Buy
Ask 0.19
Volume 763,843
Avg. Volume (20D) 5,396,431
Open 0.18
Previous Close 0.18
Day's Range 0.18 - 0.19
52-Week Range 0.13 - 1.74
Beta 0.23

About INAB

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clini...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol INAB
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for INAB stock is "Buy." The 12-month stock price forecast is $3.6, which is an increase of 1869.37% from the latest price.

Stock Forecasts
2 months ago
+13.59%
IN8bio shares are trading higher after the company... Unlock content with Pro Subscription
7 months ago
-27.33%
IN8bio shares are trading lower amid a possible selloff. The company announced it will focus on generating robust clinical data from INB-100, the ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia and said it will preserve its cash resources with cost savings and a 49% workforce reduction.